• Tue news: Merck's Keytruda stages comeback in head and neck cancer. GSK, Pfizer RSV vaccine sales fall. Astellas gene therapy bet. Extreme weather —>drug shortages. J&J discontinues bladder cancer drug. See more on our front page

Albert’s BIG pay day!













Make his compensation heavily tied to stock options at the current strike price. He and the ELT will either figure out how to focus on business growth that Wall Street rewards or he’ll be off to neutering cats at the county shelter
 




36% pay raise. 33 million dollar package. How was your pay raise???

please think about this when we get our next equity and inclusion module. Or when you this drivel is posted on LinkedIn and approved for you to “amplify “. They go big on talking equity and inclusion while they build bank, like the euro socialist they are
 




Be sure an be #pfizerproud to work for a company that allocates capital based on social conditioning and not investment opportunity.

This is what enables your CEO to get a gigantic pay raise, because what the company invests is not exposed to market risk and can be redirected for executive pay at any time.

The rich get richer and you keep fighting got those 3%-4% annual raises. Because, "equity" or something
 




Be sure an be #pfizerproud to work for a company that allocates capital based on social conditioning and not investment opportunity.

This is what enables your CEO to get a gigantic pay raise, because what the company invests is not exposed to market risk and can be redirected for executive pay at any time.

The rich get richer and you keep fighting got those 3%-4% annual raises. Because, "equity" or something

Do not disparage Alberto Bourleone's pay raise, or he may make you an offer you can't refuse.
 
















Quit writing books, or having them ghost written. Quit the ESG distractions. Run the damn business!

stock is back below 40. The entire ELT is distracted, complacent and patting themselves on the back with the stacks of money they got for the Covid flash in the pan. Get in front of Wall Street, give them compelling proof that you know how to lead a business enterprise. Or go back to writing books and spaying strays at the shelter.
 








Quit writing books, or having them ghost written. Quit the ESG distractions. Run the damn business!

stock is back below 40. The entire ELT is distracted, complacent and patting themselves on the back with the stacks of money they got for the Covid flash in the pan. Get in front of Wall Street, give them compelling proof that you know how to lead a business enterprise. Or go back to writing books and spaying strays at the shelter.
Good point made here, our stock is a dog, has been for years...
 




Good point made here, our stock is a dog, has been for years...
We set goals all through the company every year. Who sets the goals for these ELT bozos? Eliminate any incentive other than ethical performance, meaningful advancement of useful, approveable products and stock price advancements. And all ELT and Board incentives to be in options at current strike price, no grants. They have not proven an ability to grow the company value, too much time on meaningless tripe
 












Hard to argue against this, look at the stock performance over the last 10 years...The leaders sure do love to applaud themselves and sign the praises of each other thought...
Yes to both and for related reasons. Income investors were willing to stay in our dividend stock while interest rates were so low. Now that rates are up, income investors move to CDs or other safe instruments with less market risks. Institutional and growth investors have not and still don’t see a compelling forward vision from PFE leadership. Even with billions in windfall Covid sales, leadership doesn’t have a forward view that inspires investment. Writing books and paying themselves big money doesn’t bring investor confidence.
 








Good point made here, our stock is a dog, has been for years...
Reuters has an interview with AB this week. Maybe they will press on why we have billions in profits, millions in exec pay and a horribly stagnant stock price. Or will this be another fawning Covid interview with no real financial focus?
Make exec and Board compensation stock options, not grants. Build a compelling financial strategy that investors reward.
 




If IQVIA is forecasting correctly, I’m taking pension getting the freck out of here, I’ve drank the blue koolaid long enough. Time talk to the small biotech’s that head-hunters have been pitching and get a pay raise.

We can’t bank like Albert!

IQVIA Analysis:
- Most recent and future drug launches in industry are failures that don’t recoup costs
- Customers only want to see MSL’s
- Customers engagement in US market are moving towards digital
- Only 3 of the top 15 pharma will be able to see financial replace with patent expirations. MRK, LLY, JNJ
- PFE growth by acquisition model is doomed, nonorganic growth sucks except one time COVID windfall
 




Similar threads

Replies
6
Views
1K
Pfizer
anonymous
Replies
7
Views
2K
Pfizer
anonymous
Replies
6
Views
4K
Pfizer
anonymous